Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World

CONCLUSIONS: This updated analysis confirms the effectiveness of osimertinib in RW. Although the ICER of osimertinib seems not cost-effective, additional costs for the management of disease progression to old generation TKIs were not considered in this study. The BI-gap suggests RW mTTD as a more reliable measure for expense estimation.PMID:38520745 | DOI:10.1093/oncolo/oyae043

Source: The Oncologist - March 23, 2024 Category: Cancer & Oncology Authors: Giulia Pasello Martina Lorenzi Daniela Scattolin Alessandro Del Conte Fabiana Cecere Alberto Pavan Marianna Macerelli Valentina Polo Sara Pilotto Mariacarmela Santarpia Enrico Cumerlato Valentina Da Ros Giada Targato Alberto Bortolami Laura Bonanno Alessa Source Type: research